Patents by Inventor Menno Van Lookeren

Menno Van Lookeren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Affinity matured CRIg variants
    Patent number: 9234024
    Abstract: The present invention concerns affinity matured CRIg variants. In particular, the invention concerns CRIg variants having increased binding affinity to C3b and retaining selective binding to C3b over C3.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: January 12, 2016
    Assignee: GENENTECH, INC.
    Inventors: Sachdev S. Sidhu, Bing Li, Menno Van Lookeren Campagne, Christian Wiesmann
  • IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20150266953
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: December 23, 2014
    Publication date: September 24, 2015
    Applicant: GENENTECH, INC.
    Inventors: Jian CHEN, Ellen FILVAROFF, Sherman FONG, Dorothy FRENCH, Audrey GODDARD, Paul J. GODOWSKI, J. Christopher GRIMALDI, Austin L. GUMEY, Kenneth J. HILLAN, Sarah G. HYMOWITZ, Hanzhong LI, James Pan ZTUBICOKE, Melissa A. STAROVASNIK, Daniel TUMAS, Menno VAN LOOKEREN, Richard VANDLEN, Colin K. WATANABE, P. Mickey WILLIAMS, William I. WOOD, Daniel G. YANSURA
  • IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20150141283
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: September 17, 2014
    Publication date: May 21, 2015
    Applicant: GENENTECH, INC.
    Inventors: Jian CHEN, Ellen FILVAROFF, Sherman FONG, Dorothy FRENCH, Audrey GODDARD, Paul J. GODOWSKI, J. Christopher GRIMALDI, Austin L. GURNEY, Kenneth J. HILIAN, Sarah G. HYMOWITZ, Hanzhong LI, Melissa A. STAROVASNIK, Daniel TUMAS, Menno VAN LOOKEREN, Richard VANDLEN, Colin K. WATANABE, P. Mickey WILLIAMS, William I. WOOD, Daniel G. YANSURA, James PAN
  • Humanized Anti-Factor D Antibodies And Uses Thereof
    Publication number: 20140212433
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: March 5, 2014
    Publication date: July 31, 2014
    Applicant: Genentech, Inc.
    Inventors: ARTHUR HUANG, ROBERT KELLEY, HENRY LOWMAN, MENNO VAN LOOKEREN CAMPAGNE, CHARLES WINTER
  • HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF
    Publication number: 20140065137
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: September 20, 2013
    Publication date: March 6, 2014
    Applicant: GENENTECH, INC.
    Inventors: Arthur Huang, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
  • Polynucleotides encoding humanized anti-factor D antibodies
    Patent number: 8614306
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: December 24, 2013
    Assignee: Genentech, Inc.
    Inventors: Arthur Huang, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20130302333
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: June 27, 2013
    Publication date: November 14, 2013
    Applicant: GENENTECH, INC.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Weismann, Menno Van Lookeren Campagne
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8497094
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: July 30, 2013
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • IL-17 HOMOLOGOUS POLYPEPTIDES AND THEREAPEUTIC USES THEREOF
    Publication number: 20130064827
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: August 23, 2012
    Publication date: March 14, 2013
    Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Dorothy French, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gumey, Kenneth J. Hillan, Sarah G. Hymowitz, Hanzhong Li, James Pan, Melissa A. Starovasnik, Daniel Tumas, Menno Van Lookeren, Richard Vandlen, Colin K. Watanabe, P. Mickey Williams, William I. Wood, Daniel G. Yansura
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20130052685
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: July 20, 2012
    Publication date: February 28, 2013
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • C3b antibodies and methods for the prevention and treatment of complement-associated disorders
    Patent number: 8377437
    Abstract: The present invention concerns antibodies to c3b and the prevention and treatment of complement-associated disorder using such antibodies.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: February 19, 2013
    Assignee: Genentech, Inc.
    Inventor: Menno Van Lookeren Campagne
  • HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF
    Publication number: 20120328613
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: August 22, 2012
    Publication date: December 27, 2012
    Applicant: GENENTECH, INC.
    Inventors: ARTHUR HUANG, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
  • Humanized anti-factor D antibodies and uses thereof
    Patent number: 8273352
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: September 25, 2012
    Assignee: Genentech, Inc.
    Inventors: Arthur Huang, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
  • IL-17 receptor-like polypeptides and therapeutic uses thereof
    Patent number: 8273703
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: September 25, 2012
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Dorothy French, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gumey, Kenneth J. Hillan, Sarah G. Hymowitz, Hanzhong Li, James Pan, Melissa A. Starovasnik, Daniel Tumas, Menno Van Lookeren, Richard Vandlen, Colin K. Watanabe, P. Mickey Williams, William I. Wood, Daniel G. Yansura
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8268310
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: September 18, 2012
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Anti-factor B antibodies and their uses
    Publication number: 20120230997
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists.
    Type: Application
    Filed: January 31, 2012
    Publication date: September 13, 2012
    Inventors: Menno Van Lookeren Campagne, Laura Deforge
  • TREATMENT OF COMPLEMENT-ASSOCIATED DISORDERS
    Publication number: 20120189626
    Abstract: The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders.
    Type: Application
    Filed: December 15, 2011
    Publication date: July 26, 2012
    Inventors: Avi Ashkenazi, Karim Yussef Helmy, Sherman Fong, Audrey Goddard, Austin L. Gurney, Kenneth James Katschke, JR., Menno Van Lookeren, William I. Wood
  • C3b antibodies and methods for the prevention and treatment of complement-associated disorders
    Publication number: 20120128674
    Abstract: The present invention concerns antibodies to C3b and the prevention and treatment of complement-associated disorder using such antibodies.
    Type: Application
    Filed: July 18, 2011
    Publication date: May 24, 2012
    Inventor: Menno Van Lookeren Campagne
  • DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DEMYELINATING DISEASES
    Publication number: 20120128698
    Abstract: The present invention concerns the diagnosis and treatment of autoimmune demyelinating diseases, such as multiple sclerosis (MS), by means of a CLM-I agonist.
    Type: Application
    Filed: July 2, 2010
    Publication date: May 24, 2012
    Inventor: Menno van Lookeren Campagne
  • Anti-factor B antibodies and their uses
    Patent number: 8158762
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: April 17, 2012
    Assignee: Genentech, Inc.
    Inventors: Menno Van Lookeren Campagne, Laura Deforge